Table 3.
Associations of CRH score with mortality in patients with various VHD
| Univariable analysis | Multivariable analysisa | |||
|---|---|---|---|---|
| Unadjusted HR (95%CI) | P value | Adjusted HR (95%CI) | P value | |
| Total Cohort ( n = 6004) | ||||
| CRH score (per 1 point increase) | 2.719 (2.503–2.954) | < 0.001 | 2.095 (1.891–2.320) | < 0.001 |
| CRH score | ||||
| Q2 vs Q1 | 3.636 (2.241–5.898) | < 0.001 | 2.586 (1.583–4.223) | < 0.001 |
| Q3 vs Q1 | 6.293 (3.965–9.989) | < 0.001 | 3.652 (2.267–5.882) | < 0.001 |
| Q4 vs Q1 | 21.246 (13.687–32.979) | < 0.001 | 8.319 (5.182–13.355) | < 0.001 |
| AS ( n = 328) | ||||
| CRH score (per 1 point increase) | 2.086 (1.448–3.004) | < 0.001 | 1.791 (1.018–3.148) | 0.043 |
| CRH score | ||||
| Q2 vs Q1 | 1.478 (0.247–8.848) | 0.669 | 1.036 (0.157–6.813) | 0.971 |
| Q3 vs Q1 | 4.652 (1.005–21.538) | 0.049 | 2.407 (0.473–12.240) | 0.290 |
| Q4 vs Q1 | 7.873 (1.792–34.584) | 0.006 | 2.990 (0.546–16.380) | 0.207 |
| AR ( n = 780) | ||||
| CRH score (per 1 point increase) | 3.416 (2.618–4.457) | < 0.001 | 3.290 (2.245–4.821) | < 0.001 |
| CRH score | ||||
| Q2 vs Q1 | — | — | — | — |
| Q3 vs Q1 | — | — | — | — |
| Q4 vs Q1 | — | — | — | — |
| MS ( n = 320) b | ||||
| CRH score (per 1 point increase) | 7.279 (3.457–15.320) | < 0.001 | 4.986 (2.069–12.016) | < 0.001 |
| CRH score | ||||
| Q2 vs Q1 | — | — | — | — |
| Q3 vs Q1 | — | — | — | — |
| Q4 vs Q1 | — | — | — | — |
| MR ( n = 1677) | ||||
| CRH score (per 1 point increase) | 2.552 (2.161–3.014) | < 0.001 | 1.938 (1.573–2.389) | < 0.001 |
| CRH score | ||||
| Q2 vs Q1 | 2.964 (1.260–6.973) | 0.013 | 1.696 (0.708–4.064) | 0.236 |
| Q3 vs Q1 | 5.416 (2.414–12.148) | < 0.001 | 2.599 (1.118–6.044) | 0.026 |
| Q4 vs Q1 | 13.451 (6.216–29.106) | < 0.001 | 4.017 (1.720–9.381) | 0.001 |
| TR ( n = 1085) | ||||
| CRH score (per 1 point increase) | 2.676 (2.246–3.188) | < 0.001 | 2.253 (1.808–2.808) | < 0.001 |
| CRH score | ||||
| Q2 vs Q1 | 2.400 (0.922–6.247) | 0.073 | 2.167 (0.816–5.752) | 0.121 |
| Q3 vs Q1 | 3.973 (1.611–9.798) | 0.003 | 3.361 (1.318–8.571) | 0.011 |
| Q4 vs Q1 | 16.708 (7.293–38.279) | < 0.001 | 10.502 (4.315–25.557) | < 0.001 |
| MVHD ( n = 1814) | ||||
| CRH score (per 1 point increase) | 2.611 (2.255–3.024) | < 0.001 | 1.914 (1.603–2.284) | < 0.001 |
| CRH score | ||||
| Q2 vs Q1 | 1.977 (1.104–3.539) | 0.022 | 1.474 (0.817–2.657) | 0.198 |
| Q3 vs Q1 | 3.752 (2.190–6.429) | < 0.001 | 2.076 (1.182–3.647) | 0.011 |
| Q4 vs Q1 | 9.788 (5.904–16.228) | < 0.001 | 3.931 (2.258–6.844) | < 0.001 |
CRH cardio-renal-hepatic, VHD valvular heart disease, AS aortic stenosis, AR aortic regurgitation, MS mitral stenosis, MR mitral regurgitation, TR tricuspid regurgitation, MVHD multiple valvular heart disease, BMI body mass index, NYHA New York Heart Association, LA left atrial end-diastolic dimension, LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, HR hazard ratio, CI confidence interval
aAdjusted for age, sex, BMI, smoking status, hypertension, hyperlipidemia, diabetes, prior myocardial infarction, cardiomyopathy, atrial fibrillation or flutter, chronic lung disease, NYHA functional class, hemoglobin, LA, LVEDD, LVEF, pulmonary hypertension, severity of VHD, and valvular intervention
bAdjusted for age and sex